Navigation Links
Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
Date:5/19/2010

CAMBRIDGE, Massachusetts, May 19, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received the 2010 Partners in Progress Corporate Award from NORD. Shire was recognized for its efforts to accelerate the development of VPRIV(TM), a human cell line derived enzyme replacement therapy (ERT) for the treatment of Type 1 Gaucher disease, and provide the therapy to patients ahead of commercial approval through early access programs. The award was presented yesterday, May 18, 2010, at NORD's Annual Gala in Washington, D.C.

This award marks the second time in the last three years that Shire has been recognized by NORD for its contributions and ongoing commitment to improving the lives of those affected by rare diseases. In 2007, the company received a Corporate Leadership Award for the development of an ERT for Hunter syndrome.

"Gaucher disease is a debilitating condition and the past several months have been very challenging for patients and their families," said Peter L. Saltonstall, President and CEO, NORD. "Shire provided a very important treatment option at a time when it was greatly needed. We applaud their responsiveness during this difficult situation."

Each year NORD honors organizations that have made a positive contribution to further the needs of the patient community, and have inspired the public to do so as well. Shire received the NORD Corporate Award for VPRIV because of its work to make the drug available to patients impacted by the ongoing disruption in supply of the onl
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
2. Shires Replenished Portfolio Drives Excellent Quarterly Performance
3. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
4. Shire Supports Rare Disease Day 2010
5. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
6. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
7. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
8. New Shire Board Member
9. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
10. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
11. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  David Hardison, Ph.D., vice president of ... has been elected chairman of the board for ... working to establish common protocols around the use ... to electronic health records. Hardison ... with organizations across the research and health care ...
(Date:7/28/2014)...   Propeller Health , the FDA-cleared digital health ... Brad Towle as Senior Vice President, Business ... the company,s sales growth, customer acquisition and program expansion. ... his past role in the development of accountable care ... pivotal time in the industry," said David Van ...
(Date:7/28/2014)... 28, 2014 It’s a hard truth: Nearly ... to further their post-secondary education are failing to obtain a ... this year. And according to an analysis by The ... veteran students’ uninformed choice of college majors, which leads to ... the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4InterMune to Release Second Quarter Financial Results on August 6 2
... 12 Eurand N.V.,(Nasdaq: EURX ), a ... products based on its proprietary drug,formulation technologies, announced ... in the NASDAQ Biotechnology Index (Nasdaq: NBI ... Executive Officer of Eurand, commented, "We are,delighted to ...
... Pa., Nov. 9 ,Southern Research Institute and ... expanded their joint marketing agreement to allow ... biotechnology and,pharmaceutical markets. Ten months ago, the ... joint marketing agreement to collaborate in,marketing contract ...
... tests at once with minimal patient discomfort, ... announced today the launch of the ComforTen(TM) Multiple ... device features ten,surgical steel 1.2mm lancet tips, which ... is the only 10-test, self-loading,surgical steel testing device ...
Cached Biology Technology:Eurand Added to NASDAQ Biotechnology Index 2Eurand Added to NASDAQ Biotechnology Index 3Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3
(Date:7/28/2014)... that have seen an increase in so-called "nuisance flooding"--which ... storm drains and compromised infrastructure--are on the East Coast, ... nuisance flooding, caused by rising sea levels, has increased ... percent since the 1960s. , The report, Sea Level ... States, also finds Annapolis and Baltimore, Maryland, lead the ...
(Date:7/28/2014)... He calls himself the bug hunter, but the target ... be found and identified with special methods and instruments. ... State Veterinary Diagnostic Laboratory at Kansas State University, recently ... enterovirus G, which is an important find in the ... cells, but didn,t know what it was," Hause said. ...
(Date:7/28/2014)... that can help advance the genetic engineering of ... has been developed by researchers with the U.S. ... a multi-institutional partnership led by Lawrence Berkeley National ... an assay that enables scientists to identify and ... components in the biosynthesis of plant cell walls. ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3How sweet it is 2How sweet it is 3
... Catch an athlete with clear potential early in his ... years including victory in the Tour de France, and ... about what training and dedication can accomplish. , What ... out about Lance Armstrong was that from 1992-1999, the ...
... vaccines for related viruses including dengue fever. A monoclonal ... Nile virus has an intriguing secret: Contrary to scientists' ... attach to host cells. Instead, the antibody somehow stops ... "This was a complete surprise to us, but it ...
... at the University of Florida's McKnight Brain Institute have ... first time duplicates neurogenesis -- the process of generating ... in today's (June 13) Proceedings of the National Academy ... holds the promise of producing a limitless supply of ...
Cached Biology News:Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 2Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 3Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 4Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 5Lance Armstrong through a physiological lens: hard training boosts muscle power 8% 6Secrets to antibody's success against West Nile Virus surprise scientists 2Secrets to antibody's success against West Nile Virus surprise scientists 3Secrets to antibody's success against West Nile Virus surprise scientists 4For first time, brain cells generated in a dish 2For first time, brain cells generated in a dish 3
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from within ... FANCM. (Note: the amino acid sequence ... as ab27787 .) ...
Biology Products: